Open Access

Apatinib inhibits gastric carcinoma development by regulating the expression levels of IL‑17 via the Bax/Bcl‑2 signaling pathway

  • Authors:
    • Tianxi Wang
    • Jun Zhang
    • Lihong Cui
  • View Affiliations

  • Published online on: April 19, 2021     https://doi.org/10.3892/etm.2021.10086
  • Article Number: 654
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Gastric carcinoma is a common type of gastrointestinal tumor with high morbidity and mortality rates. IL‑17 is a newly discovered cytokine that has been reported to serve an important role in the development of gastric carcinoma. The potential effect of apatinib on IL‑17 expression levels in the development of gastric carcinoma has been rarely reported. The present study aimed to investigate the potential mechanism of IL‑17 and apatinib in the development of gastric carcinoma. A total of 30 tumor and para‑carcinoma tissues were collected from 30 patients with gastric carcinoma between January 2019 and December 2019 and the expression levels of IL‑17 in the tissues were analyzed by reverse transcription‑quantitative PCR and western blotting. An in vitro model of gastric carcinoma was also established using the HGC‑27 cell line, in which the cells were divided into control, IL‑17, IL‑17‑apatinib and apatinib groups. The expression levels of IL‑17, Bax, Bcl‑2 and caspase‑3 were analyzed using reverse transcription‑quantitative PCR and western blotting. An MTT assay and flow cytometry were used to analyze the proliferation and apoptosis of HGC‑27 cells, respectively, and a Transwell assay was used to analyze the invasive ability of HGC‑27 cells. The results revealed that the expression levels of IL‑17 were significantly upregulated in the gastric carcinoma tissues compared with the para‑carcinoma tissues. In vitro, IL‑17 treatment promoted the proliferation and invasive ability of HGC‑27 cells, but inhibited the apoptosis with the significantly downregulated expression levels of Bax and caspase‑3 and the upregulated expression levels of Bcl‑2 than control group. Conversely, apatinib treatment significantly inhibited the proliferative and invasive abilities of HGC‑27 cells, but promoted cell apoptosis in the IL‑17 and IL‑17‑apatinib groups.. Collectively, the present results suggested that the upregulation of IL‑17 may be associated with the occurrence and development of gastric carcinoma. The findings indicated that apatinib may inhibit gastric carcinoma development by regulating IL‑17 expression via the Bax/Bcl‑2 signaling pathway. Therefore, the present findings may enhance the current knowledge of the effect of apatinib on gastric carcinoma cells.

Related Articles

Journal Cover

June-2021
Volume 21 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang T, Zhang J and Cui L: Apatinib inhibits gastric carcinoma development by regulating the expression levels of IL‑17 via the Bax/Bcl‑2 signaling pathway. Exp Ther Med 21: 654, 2021
APA
Wang, T., Zhang, J., & Cui, L. (2021). Apatinib inhibits gastric carcinoma development by regulating the expression levels of IL‑17 via the Bax/Bcl‑2 signaling pathway. Experimental and Therapeutic Medicine, 21, 654. https://doi.org/10.3892/etm.2021.10086
MLA
Wang, T., Zhang, J., Cui, L."Apatinib inhibits gastric carcinoma development by regulating the expression levels of IL‑17 via the Bax/Bcl‑2 signaling pathway". Experimental and Therapeutic Medicine 21.6 (2021): 654.
Chicago
Wang, T., Zhang, J., Cui, L."Apatinib inhibits gastric carcinoma development by regulating the expression levels of IL‑17 via the Bax/Bcl‑2 signaling pathway". Experimental and Therapeutic Medicine 21, no. 6 (2021): 654. https://doi.org/10.3892/etm.2021.10086